Susquehanna International Group’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,975
| Closed | -$133K | – | 13344 |
|
|
2025
Q2 | $133K | Buy |
17,975
+8,332
| +86% | +$73.2K | ﹤0.01% | 11595 |
|
|
2025
Q1 | $83K | Buy |
9,643
+7,649
| +384% | +$118K | ﹤0.01% | 11654 |
|
|
2024
Q4 | $71.3K | Sell |
1,994
-998
| -33% | -$51.6K | ﹤0.01% | 11527 |
|
|
2024
Q3 | $141K | Sell |
2,992
-1,362
| -31% | -$60.1K | ﹤0.01% | 10798 |
|
|
2024
Q2 | $219K | Buy |
4,354
+535
| +14% | +$38.7K | ﹤0.01% | 10161 |
|
|
2024
Q1 | $428K | Sell |
3,819
-2,292
| -38% | -$228K | ﹤0.01% | 8888 |
|
|
2023
Q4 | $354K | Sell |
6,111
-1,123
| -16% | -$45.2K | ﹤0.01% | 9474 |
|
|
2023
Q3 | $230K | Sell |
7,234
-4,459
| -38% | -$212K | ﹤0.01% | 9923 |
|
|
2023
Q2 | $962K | Buy |
11,693
+722
| +7% | +$106K | ﹤0.01% | 6765 |
|
|
2023
Q1 | $1.13M | Buy |
10,971
+9,373
| +587% | +$1.32M | ﹤0.01% | 6501 |
|
|
2022
Q4 | $234K | Sell |
1,598
-2,499
| -61% | -$422K | ﹤0.01% | 9735 |
|
|
2022
Q3 | $692K | Buy |
4,097
+3,333
| +436% | +$542K | ﹤0.01% | 7597 |
|
|
2022
Q2 | $88K | Sell |
764
-6,187
| -89% | -$582K | ﹤0.01% | 11586 |
|
|
2022
Q1 | $693K | Buy |
6,951
+2,073
| +42% | +$242K | ﹤0.01% | 8111 |
|
|
2021
Q4 | $759K | Buy |
4,878
+1,128
| +30% | +$219K | ﹤0.01% | 8022 |
|
|
2021
Q3 | $884K | Sell |
3,750
-674
| -15% | -$197K | ﹤0.01% | 7897 |
|
|
2021
Q2 | $1.5M | Sell |
4,424
-831
| -16% | -$315K | ﹤0.01% | 6638 |
|
|
2021
Q1 | $2.13M | Buy |
5,255
+4,729
| +899% | +$2.29M | ﹤0.01% | 5785 |
|
|
2020
Q4 | $350K | Sell |
526
-2,248
| -81% | -$1.25M | ﹤0.01% | 8964 |
|
|
2020
Q3 | $1.29M | Buy |
2,774
+1,763
| +174% | +$891K | ﹤0.01% | 5516 |
|
|
2020
Q2 | $591K | Buy |
1,011
+292
| +41% | +$99.7K | ﹤0.01% | 7019 |
|
|
2020
Q1 | $105K | Buy |
+719
| New | +$126K | ﹤0.01% | 9288 |
|
|
2019
Q4 | – | Sell |
-655
| Closed | -$26K | – | 10290 |
|
|
2019
Q3 | $26K | Sell |
655
-862
| -57% | -$62.7K | ﹤0.01% | 9913 |
|
|
2019
Q2 | $154K | Buy |
+1,517
| New | +$179K | ﹤0.01% | 9347 |
|
Other funds holding MRSN
Susquehanna International Group's MRSN Position: Q3 2025 in Review
Susquehanna International Group sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 17,975 shares — an estimated $133K sold.
Susquehanna International Group first reported a position in MRSN in Q2 2019 and held it in 24 quarters. The position peaked at $2.13M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.
- Susquehanna International Group reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 17,975 Mersana Therapeutics shares in Q3 2025, an estimated $133K.
- Susquehanna International Group first reported a position in Mersana Therapeutics in Q2 2019 and held it in 24 quarters.
- Susquehanna International Group's Mersana Therapeutics position peaked at $2.13M in Q1 2021.
- 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.